Pyxis Oncology (PYXS) EBT Margin (2024 - 2025)

Pyxis Oncology (PYXS) posted quarterly EBT Margin of 154.04% for Q4 2025, up 75.96% quarter-over-quarter from 640.82% in Q2 2025.

Pyxis Oncology (PYXS) EBT Margin (2024 - 2025) Analysis & Trends

Pyxis Oncology (PYXS) has reported EBT Margin for 2 consecutive years, with 154.04% the latest figure, recorded in Q4 2025.

In Q4 2025, EBT Margin changed N/A year-over-year to 154.04%; the TTM figure through Dec 2025 stood at 574.64% (down 2980.0% YoY), while the FY2025 annual figure was 564.55%, down 7220.0% from the prior year.
EBT Margin advanced to 154.04% in Q4 2025 per PYXS's latest filing, from 640.82% in the prior quarter.
Across five years, EBT Margin topped out at 72.66% in Q1 2024 and bottomed at 640.82% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	35.61%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	35.71%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-528.97%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	18.33%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	13.77%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-2.67%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	12.09%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-25.06%
10	Pyxis Oncology	199.01 Mn	166.02 Mn	-	-

Download Data